United States - English - NLM (National Library of Medicine)

wg critical care, llc - ertapenem sodium (unii: 2t90ke67l0) (ertapenem - unii:g32f6eid2h) - ertapenem for injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated intra-abdominal infections due to escherichia coli , clostridium clostridioforme , eubacterium lentum , peptostreptococcus species, bacteroides fragilis , bacteroides distasonis , bacteroides ovatus , bacteroides thetaiotaomicron , or bacteroides uniformis . ertapenem for injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis due to staphylococcus aureus (methicillin susceptible isolates only), streptococcus agalactiae , streptococcus pyogenes , escherichia coli , klebsiella pneumoniae , proteus mirabilis , bacteroides fragilis , peptostreptococcus species, porphyromonas asaccharolytica , or prevotella bivia . ertapenem for injection has not been studied in diabetic foot infections with concomitant osteomy

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - ertapenem sodium (unii: 2t90ke67l0) (ertapenem - unii:g32f6eid2h) - ertapenem sodium 1 kg in 1 kg

United States - English - NLM (National Library of Medicine)

eugia us llc - ertapenem sodium (unii: 2t90ke67l0) (ertapenem - unii:g32f6eid2h) - ertapenem for injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated intra-abdominal infections due to escherichia coli , clostridium clostridioforme , eubacterium lentum , peptostreptococcus species, bacteroides fragilis , bacteroides distasonis , bacteroides ovatus , bacteroides thetaiotaomicron , or bacteroides uniformis . ertapenem for injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis due to staphylococcus aureus (methicillin susceptible isolates only), streptococcus agalactiae , streptococcus pyogenes , escherichia coli , klebsiella pneumoniae , proteus mirabilis , bacteroides fragilis , peptostreptococcus species, porphyromonas asaccharolytica , or prevotella bivia . ertapenem for injection has not been studied in diabetic foot infections with concomitant osteomy

United States - English - NLM (National Library of Medicine)

eugia us llc - ertapenem sodium (unii: 2t90ke67l0) (ertapenem - unii:g32f6eid2h) - ertapenem for injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated intra-abdominal infections due to escherichia coli , clostridium clostridioforme , eubacterium lentum , peptostreptococcus species, bacteroides fragilis , bacteroides distasonis , bacteroides ovatus , bacteroides thetaiotaomicron , or bacteroides uniformis . ertapenem for injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis due to staphylococcus aureus (methicillin susceptible isolates only), streptococcus agalactiae , streptococcus pyogenes , escherichia coli , klebsiella pneumoniae , proteus mirabilis , bacteroides fragilis , peptostreptococcus species, porphyromonas asaccharolytica , or prevotella bivia . ertapenem for injection has not been studied in diabetic foot infections with concomitant osteomy

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa, inc. - ertapenem sodium (unii: 2t90ke67l0) (ertapenem - unii:g32f6eid2h) - ertapenem for injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated intra-abdominal infections due to escherichia coli , clostridium clostridioforme , eubacterium lentum , peptostreptococcus species, bacteroides fragilis , bacteroides distasonis , bacteroides ovatus , bacteroides thetaiotaomicron , or bacteroides uniformis . ertapenem for injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis due to staphylococcus aureus (methicillin susceptible isolates only), streptococcus agalactiae , streptococcus pyogenes , escherichia coli , klebsiella pneumoniae , proteus mirabilis , bacteroides fragilis , peptostreptococcus species, porphyromonas asaccharolytica , or prevotella bivia . ertapenem for injection has not been studied in diabetic foot infections with concomitant osteomy

United States - English - NLM (National Library of Medicine)

hospira, inc. - ertapenem sodium (unii: 2t90ke67l0) (ertapenem - unii:g32f6eid2h) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of ertapenem for injection and other antibacterial drugs, ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. treatment ertapenem for injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see dosage and administration (2)]. ertapenem for injection is indicated for the treatment of complicated intra-abdominal infections due to escherichia coli , clostridium clostridioforme , eubacterium lentum , peptostrept

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: triethyl citrate; citric acid; magnesium stearate; sodium starch glycollate; purified talc; povidone; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; xanthan gum; polyvinyl alcohol; lecithin; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; indigo carmine; sunset yellow fcf; allura red ac; macrogol 3350 - epilepsy. primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.. mania. for the treatment of mania where other therapy has proved inadequate or is inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: purified talc; triethyl citrate; sodium starch glycollate; colloidal anhydrous silica; microcrystalline cellulose; povidone; magnesium stearate; citric acid; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; titanium dioxide; indigo carmine; sunset yellow fcf; allura red ac; polyvinyl alcohol; macrogol 3350; xanthan gum; lecithin - epilepsy. primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.. mania. for the treatment of mania where other therapy has proved inadequate or is inappropriate.

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - divalproex sodium (unii: 644vl95ao6) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg - divalproex sodium extended-release tablets are a valproate and are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features. a manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgment, aggressiveness, and possible hostility. a mixed episode is characterized by the criteria for a manic episode in conjunction with those for a major depressive episode (depressed mood, loss of interest or pleasure in nearly all activities). the efficacy of divalproex sodium extended-release tablets is based in part on studies of divalproex sodium delayed-release tablets in this indication, and was confirmed in a 3-week trial with patients meeting dsm-iv tr criteria for bipolar i disorder, manic or mixed type, who were hospitalized for acute mania [see clinical studies (

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - divalproex sodium (unii: 644vl95ao6) (valproic acid - unii:614oi1z5wi) - valproic acid 125 mg - divalproex sodium delayed-release tablets are a valproate and are indicated for the treatment of the manic episodes associated with bipolar disorder. a manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgment, aggressiveness, and possible hostility. the efficacy of divalproex sodium delayed-release tablets was established in 3 week trials with patients meeting dsm-iii-r criteria for bipolar disorder who were hospitalized for acute mania [see clinical studies (14.1)]. the safety and effectiveness of divalproex sodium delayed-release tablets for long-term use in mania, i.e., more than 3 weeks, has not been demonstrated in controlled clinical trials. therefore, healthcare providers who elect to use divalproex sodium delayed-release tablets for extended periods should continually reevaluate the long-term usefulness of the dr